Key result
Active flow adjustment for continuous-flow LVADs remains insufficiently developed for widespread clinical adoption.
There is increasing evidence for successful management of end-stage heart failure with continuous-flow left ventricular assist device (CF-LVAD) technology. However, passive flow adjustment at fixed CF-LVAD speed is susceptible to flow balancing issues as well as adverse hemodynamic effects relating to the diminished arterial pulse pressure and flow. With current therapy, flow cannot be adjusted with changes in venous return, which can vary significantly with volume status. This limits the performance and safety of CF-LVAD. Active flow adjustment strategies have been proposed to improve the synchrony between the pump and the native cardiovascular system, mimicking the Frank-Starling mechanism of the heart. These flow adjustment strategies include modulation by CF-LVAD pump speed by synchrony and maintenance of constant flow or constant pressure head, or a combination of these variables. However, none of these adjustment strategies have evolved sufficiently to gain widespread attention. Herein we review the current challenges and future directions of CF-LVAD therapy and sensor technology focusing on the development of a physiologic, long-term active flow adjustment strategy for CF-LVADs.
No takes yet. Share an insight, caveat, or question.
Tchantchaleishvili et al. (2016) conducted a review in End-stage heart failure. Physiologic active flow adjustment in continuous-flow left ventricular assist devices (CF-LVAD) vs. Passive flow adjustment at fixed CF-LVAD speed was evaluated. Active flow adjustment strategies for continuous-flow left ventricular assist devices aim to mimic the native cardiovascular system but have not yet evolved sufficiently for widespread adoption.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: